AI Tool Predicts Type 2 Diabetes Progression in Young People
Tests an AI prediction tool and phone app in youth with type 2 diabetes.
Key facts
- Who runs it
- University of California, San Francisco
- Where
- Oakland and San Francisco, United StatesSee the 2 sites
- Trial code
- Registry title
- Artificial Intelligence-based Methods to Predict Disease Progression in Youth With Type 2 Diabetes
- Status
- Not yet recruiting
- People taking part
- 50 people, planned
- Started
- Apr 2026
- Planned end
- Sept 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- phone application
- Standard of Care (SOC)
- Record updated
- 4 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for young people aged 10 to 21 who have had type 2 diabetes for at least 3 months and whose blood sugar control (HbA1c) is 7% (53 mmol/mol) or higher.
- Age
- 10 to 21 years
- Sex
- Women and men can join.
- Disease stage
- Type 2 diabetes for at least 3 months, with HbA1c of 7% (53 mmol/mol) or higher.
- Earlier treatment
- Medicines must be stable: no medicine changes and no change of basal insulin dose by more than 20% in the 2 weeks before joining.
- Biomarker or test result
- HbA1c of 7% (53 mmol/mol) or higher. Pancreatic autoantibody tests must be negative (see exclusions).
Main reasons for not taking part
- Positive pancreatic autoantibodies (GAD-65, insulin, IA-2, ICA 512, ZnT8)
- Plan for bariatric surgery during the study
- Expected use of systemic glucocorticoids during the study
- Cannot stop taking more than 500mg/day of Vitamin C during the study
- A condition that the investigator thinks would harm safety or data quality, or cause repeated hospital stays or big medicine changes
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age 10- 21 years
- Diagnosis of T2D based on clinical diagnosis or ICD 9 and 10 codes
- Duration of T2D ≥ 3 months
- HbA1C ≥ 7% which is the target HbA1C recommended by the American Diabetes Association
- Stable medication regimen (No medication changes and no change in basal insulin dose by more than 20% in the 2 weeks prior to enrollment)
- Ability to wear CGM for a total of 6 weeks while in the study
- English or Spanish speakers
- Willing to abide by recommendations and study procedures
- Willing and able to sign the Informed Consent Form (ICF) and/or has a parent or guardian willing and able to sign the ICF
Who cannot take part
- Plan for undergoing bariatric surgery during the study period
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
- Presence of a condition or abnormality that in the opinion of the Investigator would cause repeated hospitalizations or significant changes in medications
- Pancreatic autoantibody positivity (GAD-65, insulin, IA-2, ICA 512, ZnT8)
- Anticipated use of systemic glucocorticoids during the study period
- Unable to stop taking more than 500mg/day of Vitamin C during the study period as this may affect the sensor readings
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 21 years old?
Where in United States
- UCSF Benioff Children's Hospital Oakland, Pediatric Diabetes ClinicOakland, United StatesContact: Shylaja A Srinivasan, MDNot yet recruiting
- UCSF Benioff Children's Hospital San Francisco, Madison Clinic for Pediatric DiabetesSan Francisco, United StatesContact: Shylaja A Srinivasan, MDNot yet recruiting
About the trial
What the trial wants to find out
Currently, clinicians are unable to predict a patient's risk of long-term disease progression and development of a long-term complication based on the data that is available to them. The first aim of this is to develop and validate an Artificial Intelligence (AI) powered prediction model for Type 2 Diabetes (T2D) disease progression using existing data from previously collected studies and real-world electronic health medical data. Investigators will use clinical, pharmacologic, and genomic factors to develop the prediction model based on the most relevant clinical outcomes of change in Hemoglobin A1c (HbA1c) and the development of a microvascular complication.
Read full original descriptionShow less
Despite the availability of newer medication options, lifestyle intervention is not effective in most youth and current therapeutic options are ineffective at producing sustained glycemic control. Newer and innovative methods are needed to identify the youth at highest risk of progression in terms of increase in HbA1c and development of long-term complications and to motivate behavioral change in youth. The goal of this aim is to create an AI-powered digital twin model for 50 youth with T2D using their baseline clinical, genetic, pharmacologic and lifestyle data and utilize AI algorithms developed in Aim 1 to simulate disease progression and treatment response. Investigators will then evaluate the digital twin model in an randomized controlled trail and prospectively compare the generated digital twin data to observed values over one year. Investigators will also measure whether knowledge of the digital twin prediction with targeted healthcare recommendations influence medication and lifestyle change adherence in the digital twin arm (n= 25) compared to the control arm (n= 25).
The 2 groups in the trial
- Digital twin armTreatment being tested
Participants in the digital twin arm will receive information on their disease progression which will be based on projected change in HbA1C in alternative realities and specific recommendations on medication dosing and lifestyle changes based on this data. The digital twin information will be presented on an iPad in a game- like manner. The alternate realities will include scenarios of change in medication adherence, physical activity metrics, dietary changes etc.
Treatment: phone application
- Control armPlacebo, for comparison
Participants in the control arm will receive standard of care which is medication change recommendations based on HbA1C and blood glucose values every 3 months and standard lifestyle education.
Treatment: Standard of Care (SOC)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Artificial Intelligence-based Methods to Predict Disease Progression in Youth With Type 2 Diabetes: A Digital Twin Study
- Plain-language title
- AI Tool Predicts Type 2 Diabetes Progression in Young PeopleGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07116902, who can take part
- Record updated
- 4 December 2025